Total Funding
65
79
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
195073
Acrux is a dynamic Australian drug delivery business developing Company.
Past Role: Synthon, Chief Commercial Officer
About the Company
Acrux is a specialty pharmaceutical company, developing and commercialising a range of patented, patient-preferred healthcare products for global markets, using its innovative technology to administer drugs through the skin.
Acrux's product pipeline includes treatments of hormonal deficiencies, pain, central nervous system disorders and a
contraceptive. 20 human clinical trials have been completed with 8 different drugs and the lead product, Evamist(TM), is nearing the end of a phase 3 trial in the USA.
